{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:12:08Z","timestamp":1769245928717,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with no survival benefit demonstrated using palliative cytotoxic chemotherapy in the setting of metastatic MCC. Recently, immune checkpoint inhibitors (anti\u2010PD\u2010L1\/PD1) have been approved in this setting after durable clinical response was demonstrated in several clinical trials. In this series, we present a multicentre real\u2010world experience in using anti\u2010PD\u2010L1\/PD1 in advanced MCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was performed of all patients with metastatic MCC who were treated with at least one dose of anti\u2010PD\u2010L1\/PD1 presenting to Sydney West Cancer Network (Westmead, Nepean and Blacktown hospitals) was performed between 2016 and 2020. Treatment response was assessed based on morphologic and\/or metabolic changes of the disease on FDG\u2010PET\/CT scans. Primary end point investigated was objective response rate. Secondary outcomes included therapy toxicity, disease control and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen patients received anti\u2010PD\u2010L1\/PD1 with a median age of 82 (range 62\u201389). Two patients had undergone prior palliative chemotherapy. The median follow\u2010up time was 17 months (range 2\u201334). The overall, complete and partial response rates were 77% (10), 54% (7) and 23% (3), respectively. Treatment\u2010related grade 1 or 2 toxicity was experienced by 69% with only 2 cases of greater severity. The median progression\u2010free survival and overall survival were 18\u00a0months (95% CI 10\u201326\u00a0months) and 33\u00a0months (95% CI range 7.6\u201358.4\u00a0months), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Consistent with clinical trial results, anti\u2010PD\u2010L1\/PD1 therapy in this small series demonstrated efficacy and safety in patients with metastatic MCC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.13243","type":"journal-article","created":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T14:39:32Z","timestamp":1622385572000},"page":"760-767","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-787X","authenticated-orcid":false,"given":"Shaheen","family":"Hasmat","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology Crown Princess Mary Cancer Centre Westmead Hospital Westmead New South Wales Australia"},{"name":"Sydney Medical School Faculty of Medicine and Health Sciences University of Sydney Camperdown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R","family":"Howle","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology Crown Princess Mary Cancer Centre Westmead Hospital Westmead New South Wales Australia"},{"name":"Sydney Medical School Faculty of Medicine and Health Sciences University of Sydney Camperdown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deme J","family":"Karikios","sequence":"additional","affiliation":[{"name":"Sydney Medical School Faculty of Medicine and Health Sciences University of Sydney Camperdown New South Wales Australia"},{"name":"Department of Medical Oncology Nepean Cancer Care Centre Nepean New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo S","family":"Carlino","sequence":"additional","affiliation":[{"name":"Sydney Medical School Faculty of Medicine and Health Sciences University of Sydney Camperdown New South Wales Australia"},{"name":"Department of Medical Oncology Crown Princess Mary Cancer Centre Westmead Hospital Westmead New South Wales Australia"},{"name":"Melanoma Institute Australia Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0106-8325","authenticated-orcid":false,"given":"Michael J","family":"Veness","sequence":"additional","affiliation":[{"name":"Sydney Medical School Faculty of Medicine and Health Sciences University of Sydney Camperdown New South Wales Australia"},{"name":"Department of Radiation Oncology Crown Princess Mary Cancer Centre Westmead Hospital Westmead New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13407"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.124"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.77"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-62241-1_16"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2019.03.001"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000674"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01896"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12708"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2010.12.013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000700"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-02295-4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0310-x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001076"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00488-6"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15621"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0352-8"},{"key":"e_1_2_8_24_1","unstructured":"KimS. (2017).A Phase 2 Randomized Multi\u2010institutional Study of Nivolumab and Ipilimumab Versus Nivolumab Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma. Identifier NCT03071406.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03071406"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9599"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00223"},{"key":"e_1_2_8_27_1","first-page":"1363","article-title":"How we treat Merkel cell carcinoma: within and beyond current guidelines","volume":"17","author":"Park SY","year":"2021","journal-title":"Front Oncol"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.13243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1754-9485.13243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.13243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:28:00Z","timestamp":1693279680000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.13243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,30]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/1754-9485.13243"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.13243","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,30]]},"assertion":[{"value":"2021-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}